Of all the progress made in RNA and gene-based therapies, one challenge keeps resurfacing: delivery and transfection efficiency.
It’s easy to get caught up in the promise of these modalities (and for good reason). The ability to design therapies at the genetic level has opened doors that simply didn’t exist before. But translating that science into something that can actually be administered, distributed, and scaled is still far from straightforward.
If anything, the more sophisticated the therapy becomes, the more pressure it puts on the delivery system.
RNA-based therapeutics don’t behave like traditional small molecules. They’re larger, more fragile, and far more sensitive to environmental conditions. Left unprotected, they degrade quickly. Even when stabilized within LNPs, getting them into the right cells - and doing so efficiently - is its own challenge.
That’s why delivery systems have become just as important as the therapeutic payload itself.
In many cases, the success of an RNA program isn’t determined by the sequence. It’s determined by how well it is delivered.
Lipid nanoparticles have been around for a while, but over the past few years, they’ve shifted from a specialized tool to something much closer to a standard approach for RNA delivery.
There’s a practical reason for that. LNPs can encapsulate RNA, protect it from degradation, and help facilitate cellular uptake in a way that’s difficult to replicate with other systems. They also offer a level of flexibility that’s important as therapies become more targeted.
But working with LNPs isn’t as simple as adopting the concept. The formulation itself can be highly sensitive. Small changes in lipid composition, particle size, or manufacturing conditions can have a meaningful impact on performance.
And that’s where things tend to get complicated.
One of the more common issues with LNP-based programs is that early formulations don’t always translate seamlessly into later-stage outcomes. What works in a controlled development setting can become harder to reproduce at scale. Stability profiles shift, encapsulation efficiency changes, and analytical assay methods need to be refined.
Sometimes those adjustments are manageable. Other times, they require stepping back and reworking parts of the process by quality by design (QbD) to overcome the challenges.
That’s not just frustrating; it can be costly in terms of both time and momentum.
Ascendia Pharmaceutical Solutions’ work in this space reflects a slightly different mindset. Rather than treating LNP formulation as a standalone step, it’s approached as part of a broader system that includes analytical characterization and manufacturing from the outset.
Their LipidSol® platform is designed to handle a range of payloads (RNA, DNA, and even certain small molecules), but the more important piece is how that formulation work connects to what comes next.
By keeping development, analytics, and cGMP manufacturing aligned, there’s less need to reinterpret or rebuild processes as programs move forward. It doesn’t eliminate variability (nothing really does), but it makes it easier to manage.
At the same time, there’s been a noticeable shift in how gene therapies are being approached. Viral vectors still play a major role, but non-viral delivery systems are gaining traction for rare diseases and other unmet medical needs.
Part of that is driven by safety considerations or its scalability, and/or another part of it is simply flexibility, especially as more programs explore repeat dosing or more targeted delivery strategies.
That shift is still evolving, but it’s already influencing how development programs are designed.
Companies aren’t just asking whether a therapy works, they’re asking how it can be delivered in a way that’s practical over the long term.
One piece that doesn’t always get enough attention in these conversations is analytics.
With LNPs and RNA-based therapies, characterization isn’t just a box to check. Particle size distribution, encapsulation efficiency, release profiles… these aren’t minor details. They directly influence how a therapy performs.
And as formulations become more complex, the analytical methods need to be unmatched.
This is another area where having those capabilities closely tied to formulation and manufacturing can make a difference. When analytical insights feed directly back into development, adjustments can happen earlier, before the other issues start compounding.
There’s a tendency in complex programs for progress to feel nonlinear. Things move forward, then pause, then sometimes step backward before moving ahead again by process of reassessment and reiteration to achieve the optimized solutions.
In LNP and RNA-based development, that often comes down to making early decisions with the notion of first time right that don’t need to be revisited later, or at least not in a fundamental way.
RNA and gene-based therapies aren’t slowing down. If anything, they’re becoming more central to how new treatments are designed and developed.
But as that happens, delivery is no longer a secondary consideration. It’s part of the core challenge.
Companies that can navigate that complexity without losing time to avoidable setbacks are going to be in a stronger position as these modalities continue to mature.
Ascendia Pharmaceutical Solutions’ commitments in that process remain focused. They work on the parts of development where delivery, formulation, and scale continue to interplay to enable those transitions as seamlessly as possible.
It’s not the most visible part of drug development, but it’s often one of the most consequential.